Company Overview - Dyne Therapeutics (NASDAQ:DYN) is a biotechnology company focused on developing therapies for genetically driven diseases using its proprietary FORCE platform [1] Investment Insights - Chardan Capital has set a price target of $38 for DYN, indicating a potential increase of 64.71% from its current price of $16.15 [2][6] - Palo Alto Investors LP has increased its stake in DYN by 209,523 shares, valued at approximately $3.97 million, reflecting confidence in the company's growth prospects [2][6] - The fund's position in DYN rose by $12.82 million as of December 31, 2025, now holding 1,472,197 shares valued at $28.80 million, which constitutes 4.01% of its reported assets under management [3] Market Performance - DYN's stock is currently priced at $16.15, with a recent increase of $0.53, or 3.39%, and has fluctuated between $14 and $16.28 during the trading day [5] - Over the past year, DYN has reached a high of $25 and a low of $6.36, with a market capitalization of approximately $2.66 billion and a trading volume of 2,242,674 shares [5]